Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cascadia Commences First Drill Test of 1,065 g/t Gold Outcrop at Catch Property (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Infinity Pharmaceuticals Inc INFIQ

Industrials Pollution & Treatment Controls
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K... see more

Recent & Breaking News (GREY:INFIQ)

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

ACCESS Newswire October 11, 2023

Deadline Alert: Bronstein, Gewirtz & Grossman LLC Announces that Infinity Pharmaceuticals, Inc. (INFI) Investors Have Opportunity to Lead Class Action Lawsuit

ACCESS Newswire October 11, 2023

INFINITY ONGOING INVESTOR DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Infinity To Contact Him Directly To Discuss Their Options

PR Newswire October 11, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm

ACCESS Newswire October 11, 2023

INFI DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Infinity Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important October 16 Deadline in Securities Class Action - INFI

TheNewsWire October 11, 2023

Infinity Deadline Reminder

Newsfile October 10, 2023

INFI Investor Alert: Bronstein, Gewirtz & Grossman LLC Announces that Infinity Pharmaceuticals, Inc. (INFI) Investors Have Opportunity to Lead Class Action Lawsuit

ACCESS Newswire October 10, 2023

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

ACCESS Newswire October 10, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Infinity Pharmaceuticals, Inc. - INFI

PR Newswire October 9, 2023

INFI DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important October 16 Deadline in Securities Class Action - INFI

Newsfile October 9, 2023

Infinity Deadline Alert

Newsfile October 9, 2023

INFI Investor Alert: Bronstein, Gewirtz & Grossman LLC Announces that Infinity Pharmaceuticals, Inc. (INFI) Investors Have Opportunity to Lead Class Action Lawsuit

ACCESS Newswire October 9, 2023

Bronstein, Gewirtz & Grossman LLC Notifies Infinity Pharmaceuticals, Inc. (INFI) Investors of Class Action and to Actively Participate!

ACCESS Newswire October 8, 2023

Infinity Investor Shareholder Alert

Newsfile October 8, 2023

OCTOBER DEADLINE ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

ACCESS Newswire October 8, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Infinity Pharmaceuticals, Inc. - INFI

Newsfile October 7, 2023

INFI DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 16 Deadline in Securities Class Action - INFI

TheNewsWire October 7, 2023

Infinity Investor Deadline Approaching

Newsfile October 7, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

ACCESS Newswire October 7, 2023

INFI DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Infinity Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important October 16 Deadline in Securities Class Action - INFI

Newsfile October 6, 2023